Amended Report of Foreign Issuer (6-k/a)
April 27 2017 - 6:09AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
___________________
Form
6-K/A
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2017
Commission File Number: 001-32001
___________________
Aptose
Biosciences Inc.
(Translation of registrant's name into
English)
5955
Airport Road, Suite 228
Mississauga, Ontario L4V 1R9
Canada
(
Address of principal executive offices
)
___________________
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
R
£
Form 40-F
£
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1)
£
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(7)
£
|
EXPLANATORY NOTE
Aptose Biosciences Inc. (the “Registrant”) is
filing this amendment on Form 6-K/A (“Amendment”) to its Report on Form 6-K, furnished to the SEC on April 21,
2017 (the “Original 6-K”), solely to furnish a corrected version of Exhibit 99.1 to the Original 6-K. The
Original 6-K omitted to include the consent of KPMG LLP with respect to the incorporation by reference of KPMG’s audit
report to certain financial statements of the Registrant into the registration statement on Form F-3 (File No. 333-200660) of
the Registrant. Except as specifically described in this explanatory note, this Amendment does not amend, modify or update
any disclosures contained in the Original 6-K, including with respect to any events occurring after the furnishing of the
Original 6-K.
INCORPORATION BY REFERENCE
Exhibit 99.1 to this Report of Foreign Issuer on Form 6-K of
Registrant is hereby incorporated by reference into the registration statement on Form F-3 (File No. 333-200660) and into the registration
statement on Form S-8 (File No. 333-205158) of the Registrant.
DOCUMENTS FILED AS PART OF THIS FORM
6-K
See Exhibit Index
hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Aptose Biosciences Inc.
|
|
|
|
|
|
|
|
|
Date: April 26, 2017
|
|
|
|
|
By:
|
/s/ Gregory Chow
|
|
|
Name:
|
Gregory Chow
|
|
|
Title:
|
Senior Vice President and Chief Financial Officer
|
EXHIBIT INDEX
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Apr 2024 to May 2024
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From May 2023 to May 2024